# Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer

> **NCT03545711** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 42 (estimated)

## Conditions studied

- Colo-rectal Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride with Irinotecan

## Key facts

- **NCT ID:** NCT03545711
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-26
- **Primary completion:** 2019-11-24
- **Final completion:** 2020-11-24
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03545711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03545711, "Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03545711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*